Send to

Choose Destination
Chembiochem. 2018 Oct 4;19(19):2039-2044. doi: 10.1002/cbic.201800295. Epub 2018 Sep 14.

Antibody-Bactericidal Macrocyclic Peptide Conjugates To Target Gram-Negative Bacteria.

Author information

Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Visterra, Inc., 275 2nd Avenue, 4th Floor, Waltham, MA, 02451, USA.


To combat antimicrobial infections, new active molecules are needed. Antimicrobial peptides, ever abundant in nature, are a fertile starting point to develop new antimicrobial agents but suffer from low stability, low specificity, and off-target toxicity. These drawbacks have limited their development. To overcome some of these limitations, we developed antibody-bactericidal macrocyclic peptide conjugates (ABCs), in which the antibody directs the bioactive macrocyclic peptide to the targeted Gram-negative bacteria. We used cysteine SN Ar chemistry to synthesize and systematically study a library of large (>30-mer) macrocyclic antimicrobial peptides (mAMPs) to discover variants with extended proteolytic stability in human serum and low hemolytic activity while maintaining bioactivity. We then conjugated, by using sortase A, these bioactive variants onto an Escherichia coli targeted monoclonal antibody. We found that these ABCs had minimized hemolytic activity and were able to kill E. coli at nanomolar concentrations. Our findings suggest macrocyclic peptides if fused to antibodies may facilitate the discovery of new agents to treat bacterial infections.


antibacterial peptides; antibiotics; antibody-drug conjugates; macrocycles; peptide synthesis


Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center